Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

--The double hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.

Hilton LK, Tang J, Ben-Neriah S, Alcaide M, Jiang A, Grande BM, Rushton CK, Boyle M, Meissner B, Scott DW, Morin RD.

Blood. 2019 Sep 16. pii: blood.2019002600. doi: 10.1182/blood.2019002600. [Epub ahead of print]

PMID:
31527075
2.

Impact of a co-pay accumulator adjustment program on specialty drug adherence.

Sherman BW, Epstein AJ, Meissner B, Mittal M.

Am J Manag Care. 2019 Jul;25(7):335-340.

3.

Integrative genomic analysis identifies key pathogenic mechanisms in primary mediastinal large B-cell lymphoma.

Mottok A, Hung SS, Chavez EA, Woolcock B, Telenius A, Chong LC, Meissner B, Nakamura H, Rushton C, Viganò E, Sarkozy C, Gascoyne RD, Connors JM, Ben-Neriah S, Mungall A, Marra MA, Siebert R, Scott DW, Savage KJ, Steidl C.

Blood. 2019 Sep 5;134(10):802-813. doi: 10.1182/blood.2019001126. Epub 2019 Jul 10.

PMID:
31292115
4.

Relapse of a group 4 medulloblastoma after 18 years as proven by histology and DNA methylation profiling.

Ricklefs FL, Fritzsche F, Winkler B, Meissner B, Dührsen L, Westphal M, Rutkowski S, Martens T, Schüller U.

Childs Nerv Syst. 2019 Jun;35(6):1029-1033. doi: 10.1007/s00381-019-04086-3. Epub 2019 Feb 22.

PMID:
30796558
5.

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D, Takata K, Béguelin W, Duns G, Mottok A, Farinha P, Bashashati A, Saberi S, Boyle M, Meissner B, Ben-Neriah S, Woolcock BW, Telenius A, Lai D, Teater M, Kridel R, Savage KJ, Sehn LH, Morin RD, Marra MA, Shah SP, Connors JM, Gascoyne RD, Scott DW, Melnick AM, Steidl C.

Cancer Discov. 2019 Apr;9(4):546-563. doi: 10.1158/2159-8290.CD-18-1090. Epub 2019 Jan 31.

PMID:
30705065
6.

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Ennishi D, Jiang A, Boyle M, Collinge B, Grande BM, Ben-Neriah S, Rushton C, Tang J, Thomas N, Slack GW, Farinha P, Takata K, Miyata-Takata T, Craig J, Mottok A, Meissner B, Saberi S, Bashashati A, Villa D, Savage KJ, Sehn LH, Kridel R, Mungall AJ, Marra MA, Shah SP, Steidl C, Connors JM, Gascoyne RD, Morin RD, Scott DW.

J Clin Oncol. 2019 Jan 20;37(3):190-201. doi: 10.1200/JCO.18.01583. Epub 2018 Dec 3.

PMID:
30523716
7.

High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.

Chong LC, Ben-Neriah S, Slack GW, Freeman C, Ennishi D, Mottok A, Collinge B, Abrisqueta P, Farinha P, Boyle M, Meissner B, Kridel R, Gerrie AS, Villa D, Savage KJ, Sehn LH, Siebert R, Morin RD, Gascoyne RD, Marra MA, Connors JM, Mungall AJ, Steidl C, Scott DW.

Blood Adv. 2018 Oct 23;2(20):2755-2765. doi: 10.1182/bloodadvances.2018023572.

8.

Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma.

Arthur SE, Jiang A, Grande BM, Alcaide M, Cojocaru R, Rushton CK, Mottok A, Hilton LK, Lat PK, Zhao EY, Culibrk L, Ennishi D, Jessa S, Chong L, Thomas N, Pararajalingam P, Meissner B, Boyle M, Davidson J, Bushell KR, Lai D, Farinha P, Slack GW, Morin GB, Shah S, Sen D, Jones SJM, Mungall AJ, Gascoyne RD, Audas TE, Unrau P, Marra MA, Connors JM, Steidl C, Scott DW, Morin RD.

Nat Commun. 2018 Oct 1;9(1):4001. doi: 10.1038/s41467-018-06354-3.

9.

Assessment of Capture and Amplicon-Based Approaches for the Development of a Targeted Next-Generation Sequencing Pipeline to Personalize Lymphoma Management.

Hung SS, Meissner B, Chavez EA, Ben-Neriah S, Ennishi D, Jones MR, Shulha HP, Chan FC, Boyle M, Kridel R, Gascoyne RD, Mungall AJ, Marra MA, Scott DW, Connors JM, Steidl C.

J Mol Diagn. 2018 Mar;20(2):203-214. doi: 10.1016/j.jmoldx.2017.11.010. Epub 2018 Feb 8.

PMID:
29429887
10.

Neuropsychological Symptoms in Sporadic Creutzfeldt-Jakob Disease Patients in Germany.

Krasnianski A, Bohling GT, Heinemann U, Varges D, Meissner B, Schulz-Schaeffer WJ, Reif A, Zerr I.

J Alzheimers Dis. 2017;59(1):329-337. doi: 10.3233/JAD-161129.

PMID:
28598840
11.

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, Meissner B, Boyle M, Hother C, Kridel R, Lai D, Saberi S, Bashashati A, Shah SP, Morin RD, Marra MA, Savage KJ, Sehn LH, Steidl C, Connors JM, Gascoyne RD, Scott DW.

Blood. 2017 May 18;129(20):2760-2770. doi: 10.1182/blood-2016-11-747022. Epub 2017 Mar 28.

PMID:
28351934
12.

Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.

Bashash M, Connors JM, Gascoyne RD, Meissner B, Schuetz JM, Leach S, Slack GW, Berry BR, Hu H, Sehn LH, Brooks-Wilson AR, Spinelli JJ.

Haematologica. 2017 May;102(5):e199-e202. doi: 10.3324/haematol.2016.159087. Epub 2017 Feb 2. No abstract available.

13.

Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study.

Kridel R, Chan FC, Mottok A, Boyle M, Farinha P, Tan K, Meissner B, Bashashati A, McPherson A, Roth A, Shumansky K, Yap D, Ben-Neriah S, Rosner J, Smith MA, Nielsen C, Giné E, Telenius A, Ennishi D, Mungall A, Moore R, Morin RD, Johnson NA, Sehn LH, Tousseyn T, Dogan A, Connors JM, Scott DW, Steidl C, Marra MA, Gascoyne RD, Shah SP.

PLoS Med. 2016 Dec 13;13(12):e1002197. doi: 10.1371/journal.pmed.1002197. eCollection 2016 Dec.

14.

A time-and-motion approach to micro-costing of high-throughput genomic assays.

Costa S, Regier DA, Meissner B, Cromwell I, Ben-Neriah S, Chavez E, Hung S, Steidl C, Scott DW, Marra MA, Peacock SJ, Connors JM.

Curr Oncol. 2016 Oct;23(5):304-313. Epub 2016 Oct 25.

15.

Cell of origin of transformed follicular lymphoma.

Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y, Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B, Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM, Scott DW, Gascoyne RD.

Blood. 2015 Oct 29;126(18):2118-27. doi: 10.1182/blood-2015-06-649905. Epub 2015 Aug 25.

16.

Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies.

Scott DW, Mottok A, Ennishi D, Wright GW, Farinha P, Ben-Neriah S, Kridel R, Barry GS, Hother C, Abrisqueta P, Boyle M, Meissner B, Telenius A, Savage KJ, Sehn LH, Slack GW, Steidl C, Staudt LM, Connors JM, Rimsza LM, Gascoyne RD.

J Clin Oncol. 2015 Sep 10;33(26):2848-56. doi: 10.1200/JCO.2014.60.2383. Epub 2015 Aug 3.

17.

Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.

An J, Niu F, Lang DT, Jazdzewski KP, Le PT, Rashid N, Meissner B, Mendes R, Dills DG, Aranda G, Bruno A.

J Am Heart Assoc. 2015 Jul 17;4(7). pii: e001921. doi: 10.1161/JAHA.115.001921.

18.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia.

Zaliova M, Zimmermannova O, Dörge P, Eckert C, Möricke A, Zimmermann M, Stuchly J, Teigler-Schlegel A, Meissner B, Koehler R, Bartram CR, Karawajew L, Rhein P, Zuna J, Schrappe M, Cario G, Stanulla M.

Leukemia. 2015 May;29(5):1222. doi: 10.1038/leu.2015.77. No abstract available.

PMID:
25945612
19.

I Would Rather Just Go Through With It Than Be Called a Wussy: An Exploration of How a Group of Young South African Men Think and Talk About Suicide.

Meissner B, Bantjes J, Kagee A.

Am J Mens Health. 2016 Jul;10(4):338-48. doi: 10.1177/1557988314568183. Epub 2015 Jan 27.

20.

Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.

Meissner B, Trivedi D, You M, Rosenblatt L.

J Med Econ. 2014 Apr;17(4):259-65. doi: 10.3111/13696998.2014.893241. Epub 2014 Feb 27.

PMID:
24575891
21.

Pharmacological and genomic profiling identifies NF-κB-targeted treatment strategies for mantle cell lymphoma.

Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, Farsidjani A, Derti A, Rakiec D, Naylor T, Pfister E, Kovats S, Kim S, Dietze K, Dörken B, Steidl C, Tzankov A, Hummel M, Monahan J, Morrissey MP, Fritsch C, Sellers WR, Cooke VG, Gascoyne RD, Lenz G, Stegmeier F.

Nat Med. 2014 Jan;20(1):87-92. doi: 10.1038/nm.3435. Epub 2013 Dec 22.

PMID:
24362935
22.

Comprehensive assessment of hormones, phytoestrogens, and estrogenic activity in an anaerobic swine waste lagoon.

Yost EE, Meyer MT, Dietze JE, Meissner BM, Worley-Davis L, Williams CM, Lee B, Kullman SW.

Environ Sci Technol. 2013 Dec 3;47(23):13781-90. doi: 10.1021/es4026408. Epub 2013 Nov 12.

23.

ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia.

Zaliova M, Zimmermannova O, Dörge P, Eckert C, Möricke A, Zimmermann M, Stuchly J, Teigler-Schlegel A, Meissner B, Koehler R, Bartram CR, Karawajew L, Rhein P, Zuna J, Schrappe M, Cario G, Stanulla M.

Leukemia. 2014 Jan;28(1):182-5. doi: 10.1038/leu.2013.282. Epub 2013 Sep 27. No abstract available. Erratum in: Leukemia. 2015 May;29(5):1222.

PMID:
24072102
24.

Frequent and sex-biased deletion of SLX4IP by illegitimate V(D)J-mediated recombination in childhood acute lymphoblastic leukemia.

Meissner B, Bartram T, Eckert C, Trka J, Panzer-Grümayer R, Hermanova I, Ellinghaus E, Franke A, Möricke A, Schrauder A, Teigler-Schlegel A, Dörge P, von Stackelberg A, Basso G, Bartram CR, Kirschner-Schwabe R, Bornhäuser B, Bourquin JP, Cazzaniga G, Hauer J, Attarbaschi A, Izraeli S, Zaliova M, Cario G, Zimmermann M, Avigad S, Sokalska-Duhme M, Metzler M, Schrappe M, Koehler R, Te Kronnie G, Stanulla M.

Hum Mol Genet. 2014 Feb 1;23(3):590-601. doi: 10.1093/hmg/ddt447. Epub 2013 Sep 17.

25.

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Morin RD, Mungall K, Pleasance E, Mungall AJ, Goya R, Huff RD, Scott DW, Ding J, Roth A, Chiu R, Corbett RD, Chan FC, Mendez-Lago M, Trinh DL, Bolger-Munro M, Taylor G, Hadj Khodabakhshi A, Ben-Neriah S, Pon J, Meissner B, Woolcock B, Farnoud N, Rogic S, Lim EL, Johnson NA, Shah S, Jones S, Steidl C, Holt R, Birol I, Moore R, Connors JM, Gascoyne RD, Marra MA.

Blood. 2013 Aug 15;122(7):1256-65. doi: 10.1182/blood-2013-02-483727. Epub 2013 May 22.

26.

Direct association of the reticulon protein RTN1A with the ryanodine receptor 2 in neurons.

Kaya L, Meissner B, Riedl MC, Muik M, Schwarzer C, Ferraguti F, Sarg B, Lindner H, Schweigreiter R, Knaus HG, Romanin C, Bandtlow CE.

Biochim Biophys Acta. 2013 Jun;1833(6):1421-33. doi: 10.1016/j.bbamcr.2013.02.012. Epub 2013 Feb 27.

27.

The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma.

Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW, Moore R, Mungall AJ, Marra MA, Connors JM, Steidl C, Gascoyne RD.

Blood. 2013 Apr 18;121(16):3161-4. doi: 10.1182/blood-2013-01-478834. Epub 2013 Feb 13.

PMID:
23407552
28.

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma.

Scott DW, Chan FC, Hong F, Rogic S, Tan KL, Meissner B, Ben-Neriah S, Boyle M, Kridel R, Telenius A, Woolcock BW, Farinha P, Fisher RI, Rimsza LM, Bartlett NL, Cheson BD, Shepherd LE, Advani RH, Connors JM, Kahl BS, Gordon LI, Horning SJ, Steidl C, Gascoyne RD.

J Clin Oncol. 2013 Feb 20;31(6):692-700. doi: 10.1200/JCO.2012.43.4589. Epub 2012 Nov 26.

29.

Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.

Volejnikova J, Mejstrikova E, Dörge P, Meissner B, Zimmermannova O, Svojgr K, Stanulla M, Cario G, Schrappe M, Stary J, Hrusak O, Trka J, Fronkova E.

Pediatr Blood Cancer. 2013 Mar;60(3):420-7. doi: 10.1002/pbc.24299. Epub 2012 Sep 19.

PMID:
22997141
30.

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.

Dörge P, Meissner B, Zimmermann M, Möricke A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel A, Ratei R, Ludwig WD, Koehler R, Bartram CR, Schrappe M, Stanulla M, Cario G.

Haematologica. 2013 Mar;98(3):428-32. doi: 10.3324/haematol.2011.056135. Epub 2012 Aug 8.

31.

Why is warfarin underused for stroke prevention in atrial fibrillation? A detailed review of electronic medical records.

Rosenman MB, Baker L, Jing Y, Makenbaeva D, Meissner B, Simon TA, Wiederkehr D, Deitelzweig S.

Curr Med Res Opin. 2012 Sep;28(9):1407-14. Epub 2012 Jul 26. Review.

PMID:
22746356
32.

Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.

Lauten M, Möricke A, Beier R, Zimmermann M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C, Niggli F, Riehm H, Schrappe M.

Haematologica. 2012 Jul;97(7):1048-56. doi: 10.3324/haematol.2011.047613. Epub 2012 Jan 22.

33.

Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

Kridel R, Meissner B, Rogic S, Boyle M, Telenius A, Woolcock B, Gunawardana J, Jenkins C, Cochrane C, Ben-Neriah S, Tan K, Morin RD, Opat S, Sehn LH, Connors JM, Marra MA, Weng AP, Steidl C, Gascoyne RD.

Blood. 2012 Mar 1;119(9):1963-71. doi: 10.1182/blood-2011-11-391474. Epub 2011 Dec 30.

PMID:
22210878
34.

Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemia.

Ellinghaus E, Stanulla M, Richter G, Ellinghaus D, te Kronnie G, Cario G, Cazzaniga G, Horstmann M, Panzer Grümayer R, Cavé H, Trka J, Cinek O, Teigler-Schlegel A, ElSharawy A, Häsler R, Nebel A, Meissner B, Bartram T, Lescai F, Franceschi C, Giordan M, Nürnberg P, Heinzow B, Zimmermann M, Schreiber S, Schrappe M, Franke A.

Leukemia. 2012 May;26(5):902-9. doi: 10.1038/leu.2011.302. Epub 2011 Nov 11.

35.

Low platelet counts after induction therapy for childhood acute lymphoblastic leukemia are strongly associated with poor early response to treatment as measured by minimal residual disease and are prognostic for treatment outcome.

Zeidler L, Zimmermann M, Möricke A, Meissner B, Bartels D, Tschan C, Schrauder A, Cario G, Goudeva L, Jäger S, Ratei R, Ludwig WD, Teigler-Schlegel A, Skokowa J, Koehler R, Bartram CR, Riehm H, Schrappe M, Welte K, Stanulla M.

Haematologica. 2012 Mar;97(3):402-9. doi: 10.3324/haematol.2011.045229. Epub 2011 Nov 4.

36.

Chemical engineering of Mycobacterium tuberculosis dodecin hybrids.

Vinzenz X, Grosse W, Linne U, Meissner B, Essen LO.

Chem Commun (Camb). 2011 Oct 21;47(39):11071-3. doi: 10.1039/c1cc12929e. Epub 2011 Sep 6.

PMID:
21897938
37.

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M, Jackman S, Krzywinski M, Scott DW, Trinh DL, Tamura-Wells J, Li S, Firme MR, Rogic S, Griffith M, Chan S, Yakovenko O, Meyer IM, Zhao EY, Smailus D, Moksa M, Chittaranjan S, Rimsza L, Brooks-Wilson A, Spinelli JJ, Ben-Neriah S, Meissner B, Woolcock B, Boyle M, McDonald H, Tam A, Zhao Y, Delaney A, Zeng T, Tse K, Butterfield Y, Birol I, Holt R, Schein J, Horsman DE, Moore R, Jones SJ, Connors JM, Hirst M, Gascoyne RD, Marra MA.

Nature. 2011 Jul 27;476(7360):298-303. doi: 10.1038/nature10351.

38.

Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment.

Schmitz M, Breithaupt P, Scheidegger N, Cario G, Bonapace L, Meissner B, Mirkowska P, Tchinda J, Niggli FK, Stanulla M, Schrappe M, Schrauder A, Bornhauser BC, Bourquin JP.

Blood. 2011 Aug 18;118(7):1854-64. doi: 10.1182/blood-2010-11-320309. Epub 2011 Jun 13.

PMID:
21670474
39.

Determining the sub-cellular localization of proteins within Caenorhabditis elegans body wall muscle.

Meissner B, Rogalski T, Viveiros R, Warner A, Plastino L, Lorch A, Granger L, Segalat L, Moerman DG.

PLoS One. 2011;6(5):e19937. doi: 10.1371/journal.pone.0019937. Epub 2011 May 17.

40.

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.

Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, Johnson NA, Zhao Y, Telenius A, Neriah SB, McPherson A, Meissner B, Okoye UC, Diepstra A, van den Berg A, Sun M, Leung G, Jones SJ, Connors JM, Huntsman DG, Savage KJ, Rimsza LM, Horsman DE, Staudt LM, Steidl U, Marra MA, Gascoyne RD.

Nature. 2011 Mar 17;471(7338):377-81. doi: 10.1038/nature09754. Epub 2011 Mar 2.

41.

Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.

Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA.

Blood. 2011 Feb 24;117(8):2451-9. doi: 10.1182/blood-2010-11-321208. Epub 2010 Dec 29.

42.

Effectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational study.

D'Souza A, Meissner BL, Tang B, McKenzie RS, Piech CT.

Am Health Drug Benefits. 2010 Jul;3(4):266-73.

43.

Clinical features of rapidly progressive Alzheimer's disease.

Schmidt C, Redyk K, Meissner B, Krack L, von Ahsen N, Roeber S, Kretzschmar H, Zerr I.

Dement Geriatr Cogn Disord. 2010;29(4):371-8. doi: 10.1159/000278692. Epub 2010 May 5.

PMID:
20453509
44.

Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease.

Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, Sanchez-Juan P.

Brain. 2009 Oct;132(Pt 10):2659-68. doi: 10.1093/brain/awp191. Epub 2009 Sep 22. Erratum in: Brain. 2012 Apr;135(Pt 4):1335.

45.

An integrated strategy to study muscle development and myofilament structure in Caenorhabditis elegans.

Meissner B, Warner A, Wong K, Dube N, Lorch A, McKay SJ, Khattra J, Rogalski T, Somasiri A, Chaudhry I, Fox RM, Miller DM 3rd, Baillie DL, Holt RA, Jones SJ, Marra MA, Moerman DG.

PLoS Genet. 2009 Jun;5(6):e1000537. doi: 10.1371/journal.pgen.1000537. Epub 2009 Jun 26.

46.

Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders.

Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A, Meissner B, Zerr I.

J Alzheimers Dis. 2009;17(4):863-73. doi: 10.3233/JAD-2009-1110.

47.

MRI lesion profiles in sporadic Creutzfeldt-Jakob disease.

Meissner B, Kallenberg K, Sanchez-Juan P, Collie D, Summers DM, Almonti S, Collins SJ, Smith P, Cras P, Jansen GH, Brandel JP, Coulthart MB, Roberts H, Van Everbroeck B, Galanaud D, Mellina V, Will RG, Zerr I.

Neurology. 2009 Jun 9;72(23):1994-2001. doi: 10.1212/WNL.0b013e3181a96e5d.

PMID:
19506221
48.

MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease.

Meissner B, Kallenberg K, Sanchez-Juan P, Ramljak S, Krasnianski A, Heinemann U, Eigenbrod S, Gelpi E, Barsic B, Kretzschmar HA, Schulz-Schaeffer WJ, Knauth M, Zerr I.

J Neurol. 2009 Mar;256(3):355-63. doi: 10.1007/s00415-009-0026-z. Epub 2009 Jan 23.

PMID:
19159063
49.

A United States cost-benefit comparison of an apodized, diffractive, presbyopia-correcting, multifocal intraocular lens and a conventional monofocal lens.

Maxwell WA, Waycaster CR, D'Souza AO, Meissner BL, Hileman K.

J Cataract Refract Surg. 2008 Nov;34(11):1855-61. doi: 10.1016/j.jcrs.2008.07.024.

PMID:
19006730
50.

Allogeneic blood SCT for children with Hurler's syndrome: results from the German multicenter approach MPS-HCT 2005.

Sauer M, Meissner B, Fuchs D, Gruhn B, Kabisch H, Erttmann R, Suttorp M, Beilken A, Luecke T, Welte K, Grigull L, Sykora KW.

Bone Marrow Transplant. 2009 Mar;43(5):375-81. doi: 10.1038/bmt.2008.328. Epub 2008 Oct 13.

PMID:
18850023

Supplemental Content

Loading ...
Support Center